comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 00:25:52 - browse：656

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

WSS

Living with Fabry disease, a condition that causes chronic pain

Beach reads and more: STAT's 2023 summer book list

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Palantir health business leans on meeting customers’ needs

Does good food count as health care? Study aims to find out

N.Y. state detects polio case, first in the U.S. since 2013

focus

comprehensive

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In key trial, Verve's treatment lowers cholesterol levels in patients

Cancer drug shortages should be causing more outrage

Petition to FDA: Get the lead out of consumer hair dyes

DIEP, the 'gold standard' of breast reconstruction, is under threat

Anthos stroke drug appears safer than common blood thinner

Medical records are filled with copy

Charles Manson follower Leslie Van Houten released from prison after 53 years

How one medical school became remarkably diverse

Anthos stroke drug appears safer than common blood thinner

hotspot

CRISPR pioneers react to Casgevy, first gene

N.Y. state detects polio case, first in the U.S. since 2013

How the political right came to back psychedelics to treat trauma

Oak trusses raised to roof of fire

What to know about OceanGate, the company behind the missing Titanic submersible

HCA discloses massive data breach affecting 11 million patients

knowledge

focus

entertainment

focus